中华肾脏病杂志
中華腎髒病雜誌
중화신장병잡지
2011年
7期
511-514
,共4页
透析%贫血%抗EPO抗体%纯红细胞再生障碍性贫血
透析%貧血%抗EPO抗體%純紅細胞再生障礙性貧血
투석%빈혈%항EPO항체%순홍세포재생장애성빈혈
Dialysis%Anemia%Anti-erythropoietin antibody%Pure red cell aplasia
目的 检测透析患者红细胞生成素(EPO)抗体水平及探讨其临床意义.方法 本院80例维持性血液透析患者和30例维持性腹膜透析患者为对象.用酶联免疫吸附法(ELISA)检测EPO抗体.用电化学发光法榆测全段甲状旁腺素(iPTH).用常规方法检测血红蛋白(Hb)、BUN、Scr、C反应蛋白(CRP).分析透析患者EPO抗体水平与Hb、BUN、Scr、iPTH、CRP的关系.分析不同基础病患者与EPO抗体、Hb、BUN、Scr、iPTH、CRP的关系.研究EPO抗体和贫血关系.结果 透析患者EPO抗体水平显著高于健康人,差异有统计学意义(P＜0.05),而血透患者与腹透患者问EPO抗体水平差异无统计学意义.不同基础病的EPO抗体水平、Hb、BUN、Scr、iPTH、CRP差异无统计学意义.透析患者Hb与EPO抗体、CRP呈负相关(r=-0.56、-0.20,P＜0.05),而与BUN、Scr、iPTH均无相关;EPO抗体与BUN、Scr、iPTH、CRP均无相关.1例应用重组人红细胞生成素(rHuEPO,环尔博)患者EPO抗体为43.63 U/L,骨髓活检示红细胞系增生低下--纯红细胞再生障碍性贫血.结论 透析患者EPO抗体水平显著高于健康人.血透患者与腹透患者问EPO抗体水平差异无统计学意义.透析患者EPO抗体与BUN、Scr、iPTH、CRP无相关.透析患者Hb与EPO抗体、CRP呈负相关.使用rHuEPO能产生抗体,可导致骨髓红细胞系增生低下,加重贫血.
目的 檢測透析患者紅細胞生成素(EPO)抗體水平及探討其臨床意義.方法 本院80例維持性血液透析患者和30例維持性腹膜透析患者為對象.用酶聯免疫吸附法(ELISA)檢測EPO抗體.用電化學髮光法榆測全段甲狀徬腺素(iPTH).用常規方法檢測血紅蛋白(Hb)、BUN、Scr、C反應蛋白(CRP).分析透析患者EPO抗體水平與Hb、BUN、Scr、iPTH、CRP的關繫.分析不同基礎病患者與EPO抗體、Hb、BUN、Scr、iPTH、CRP的關繫.研究EPO抗體和貧血關繫.結果 透析患者EPO抗體水平顯著高于健康人,差異有統計學意義(P＜0.05),而血透患者與腹透患者問EPO抗體水平差異無統計學意義.不同基礎病的EPO抗體水平、Hb、BUN、Scr、iPTH、CRP差異無統計學意義.透析患者Hb與EPO抗體、CRP呈負相關(r=-0.56、-0.20,P＜0.05),而與BUN、Scr、iPTH均無相關;EPO抗體與BUN、Scr、iPTH、CRP均無相關.1例應用重組人紅細胞生成素(rHuEPO,環爾博)患者EPO抗體為43.63 U/L,骨髓活檢示紅細胞繫增生低下--純紅細胞再生障礙性貧血.結論 透析患者EPO抗體水平顯著高于健康人.血透患者與腹透患者問EPO抗體水平差異無統計學意義.透析患者EPO抗體與BUN、Scr、iPTH、CRP無相關.透析患者Hb與EPO抗體、CRP呈負相關.使用rHuEPO能產生抗體,可導緻骨髓紅細胞繫增生低下,加重貧血.
목적 검측투석환자홍세포생성소(EPO)항체수평급탐토기림상의의.방법 본원80례유지성혈액투석환자화30례유지성복막투석환자위대상.용매련면역흡부법(ELISA)검측EPO항체.용전화학발광법유측전단갑상방선소(iPTH).용상규방법검측혈홍단백(Hb)、BUN、Scr、C반응단백(CRP).분석투석환자EPO항체수평여Hb、BUN、Scr、iPTH、CRP적관계.분석불동기출병환자여EPO항체、Hb、BUN、Scr、iPTH、CRP적관계.연구EPO항체화빈혈관계.결과 투석환자EPO항체수평현저고우건강인,차이유통계학의의(P＜0.05),이혈투환자여복투환자문EPO항체수평차이무통계학의의.불동기출병적EPO항체수평、Hb、BUN、Scr、iPTH、CRP차이무통계학의의.투석환자Hb여EPO항체、CRP정부상관(r=-0.56、-0.20,P＜0.05),이여BUN、Scr、iPTH균무상관;EPO항체여BUN、Scr、iPTH、CRP균무상관.1례응용중조인홍세포생성소(rHuEPO,배이박)환자EPO항체위43.63 U/L,골수활검시홍세포계증생저하--순홍세포재생장애성빈혈.결론 투석환자EPO항체수평현저고우건강인.혈투환자여복투환자문EPO항체수평차이무통계학의의.투석환자EPO항체여BUN、Scr、iPTH、CRP무상관.투석환자Hb여EPO항체、CRP정부상관.사용rHuEPO능산생항체,가도치골수홍세포계증생저하,가중빈혈.
Objective To investigate the anti-erythropoietin antibody level and its clinical significance in maintenance dialysis patients. Methods Eighty maintenance hemodialysis (HD) and 30 peritoneal dialysis (PD) patients were enrolled in the study. Serum anti-erythropoietin antibody levels of above 110 dialysis patients were measured by ELISA. Immunoreactive parathyroid hormone (iPTH), Scr, BUN, Hb, and CRP were determined by conventional methods at the same time. Correlations among these indexes were examined. Results The anti-erythropoietin antibody levels of the dialysis patients were significantly higher than those of healthy people (P＜0.05), but no significant difference was found between HD patients and PD patients. There were no significant differences of anti-erythropoietin antibody, Hb, BUN, Scr, iPTH and CRP among different primary diseases. Hb was negatively correlated with anti-erythropoietin antibody and CRP (r=-0.56, -0.20,P ＜0.05), but was not correlated with BUN, Scr, iPTH. There was no correlation of antierythropoietin antibody with BUN, Scr, CRP and iPTH. One patient receiving recombinant human erythropoietin (rHuEPO) treatment with anti-erythropoietin antibody 43.63 U/L developed pure red cell aplasia diagnosed by marrow biopsy. Conclusions The anti-erythropoietin antibody levels of the dialysis patients are significantly higher as compared to healthy people, but are not significantly different between HD and PD patients. Anti-erythropoietin antibody is not correlated with BUN, Scr,iPTH and CRP. Hb is negatively correlated with anti-erythropoietin antibody and CRP. The rHuEPO can induce the anti-erythropoietin antibody leading to pure red cell aplasia in dialysis patients.
